Switch to: Citations

Add references

You must login to add references.
  1. Beyond Cost‐Benefit Analysis in the Governance of Synthetic Biology.Wendell Wallach, Marc Saner & Gary Marchant - 2018 - Hastings Center Report 48 (S1):70-77.
    For many innovations, oversight fits nicely within existing governance mechanisms; nevertheless, others pose unique public health, environmental, and ethical challenges. Synthetic artemisinin, for example, has many precursors in laboratory‐developed drugs that emulate natural forms of the same drug. The policy challenges posed by synthetic artemisinin do not differ significantly in kind from other laboratory‐formulated drugs. Synthetic biofuels and gene drives, however, fit less clearly into existing governance structures. How many of the new categories of products require new forms of regulatory (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • The Precautionary Attitude: Asking Preliminary Questions.Jonathan Wolff - 2014 - Hastings Center Report 44 (S5):27-28.
    Innovation in basic science is often a cause for won­der and excitement. Those associated with a new development are quick to point out the anticipated benefits: a cure for cancer or dementia, an end to unsafe water or hunger. These advocates are slower to draw at­tention to the possible costs, which may become known only much later. It is always hard to have an accurate overview, as it is almost impossible to predict the total effects of the widespread adoption of (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations  
  • From CBA to Precautionary Appraisal: Practical Responses to Intractable Problems.Andrew Stirling & Josie Coburn - 2018 - Hastings Center Report 48 (S1):78-87.
    The purpose of this essay is to critically review the design of methods for ethically robust forms of technology appraisal in the regulation of research and innovation in synthetic biology. It will focus, in particular, on the extent to which cost‐benefit analysis offers a basis for informing decisions about which technological pathways to pursue and which to discourage. A further goal is to consider what (if anything) the precautionary principle might offer in enabling better decisions. And this, in turn, raises (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Lessons from Environmental Regulation.Amy Sinden - 2018 - Hastings Center Report 48 (S1):56-64.
    Much of the most substantive and in‐depth experience with formal cost‐benefit analysis in the public policy realm has occurred in the context of federal environmental regulation in the United States. This experience has many important lessons to teach in the realm of synthetic biology. Indeed, many of the dangers and pitfalls that arise when decision‐makers use formal CBA to evaluate environmental regulation seem likely to arise in the synthetic biology context as well, sometimes in particularly troubling forms. Unfortunately, while in (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Behavioral Economics and the Public Acceptance of Synthetic Biology.Adam Oliver - 2018 - Hastings Center Report 48 (S1):50-55.
    Different applications of synthetic biology are alike in that their possible negative consequences are highly uncertain, potentially catastrophic, and perhaps irreversible; therefore, they are also alike in that public attitudes about them are fertile ground for behavioral economic phenomena. Findings from behavioral economics suggest that people may not respond to such applications according to the normal rules of economic evaluation, by which the value of an outcome is multiplied by the mathematical probability that the outcome will occur. Possibly, then, synthetic (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • Benefit‐Cost Analysis and Emerging Technologies.Brian Mannix - 2018 - Hastings Center Report 48 (S1):12-20.
    Emerging technologies are, by definition, full of surprises: developments that we cannot fully anticipate and that might have some bad outcomes as well as good ones. This presents a challenge for anyone trying to make forward‐looking policy decisions, including those who apply benefit‐cost analysis. BCA is now widely known and used, but it is also widely misunderstood—by many of its advocates as well as its detractors. In this essay, I will begin by examining some of the strengths and weaknesses of (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Demystifying Evidence‐Based Policy Analysis by Revealing Hidden Value‐Laden Constraints.Adam M. Finkel - 2018 - Hastings Center Report 48 (S1):21-49.
    Consider any choice that affects some social policy. A decision that considers evidence will, at its heart, contain some kind of explicit or implicit “because” statement: “We are doing X because the evidence says Y.” But can evidence ever truly speak for itself, in the sense of being reducible to objective utterances that are either correct or in need of correction? Before answering, consider what you'd prefer. Would you rather receive evidence that was free of any value judgments imposed by (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Integrating Scenario Planning and Cost‐Benefit Methods.Stephen C. Aldrich - 2018 - Hastings Center Report 48 (S1):65-69.
    By their nature, the most vexing social problems reflect collisions between social and economic interests of parties with highly divergent views and perspectives on the cause and character of what is at issue and the consequences that flow from it. Conflicts around biotechnology applications are good examples of these problems. When considering the potential consequences of proposed biotechnology applications, an enormous range of perspectives arise reflecting the breadth of different and often competing interests with a stake in life's future.This essay (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation